Canada's pharmaceutical industry is at a crossroads, and the decisions made now could have life-altering consequences for its citizens. The current parliamentary session includes two studies that may seem unassuming, but they hold the key to the nation's medical future.
These studies, conducted by Parliamentary Standing Committees, delve into the complex world of medical innovation, pandemic preparedness, and access to life-saving medicines. But here's where it gets controversial: the Canadian government's approach to public investment in research and development (R&D) and biomanufacturing is under scrutiny.
The first study, titled "Private Sector Investment in Research and Development in Canada," is a bit of a misnomer. It's actually about commercializing innovations from Canadian universities to boost the economy. This means transferring publicly funded research to private companies, which then control who accesses these innovations and at what cost. This raises a critical question: should life-saving research be controlled by private interests?
The COVID-19 pandemic exposed Canada's pharmaceutical vulnerabilities. The second study, focusing on "Canada's Pharmaceutical Sovereignty," highlights the country's struggle with drug shortages and limited domestic production capacity. Canada's dependence on other nations for medicines and their ingredients became glaringly obvious during the pandemic, with the first domestic COVID-19 vaccine doses only produced in September 2025.
And this is the part most people miss: while public investment in biomanufacturing is crucial, the current approach often benefits private companies, including multinationals, more than the public. For instance, the University of British Columbia's innovations during the pandemic, such as the monoclonal antibody treatment bamlanivimab, were spun off into private companies, which then received substantial public funding. Yet, the main beneficiaries were private interests, as seen with AbCellera's stock market success.
The issue of access to medicines is further complicated by the absence of conditions tied to public funding. Canada faced challenges accessing mRNA vaccines and ended up funding the WHO's mRNA Tech Transfer Hub in South Africa to reverse-engineer a vaccine technology initially funded by Canadians. This begs the question: should public funds be used to support private companies without ensuring access to the resulting medicines?
The situation is even more dire for Essential Medicines identified by the WHO, which are not sold in Canada due to profitability concerns. This leaves patients struggling to access life-saving treatments. Canada's reliance on profit-driven commercial interests also hinders the market entry of Canadian research breakthroughs, as seen with the Ebola vaccine saga.
Canada has the chance to shift its strategy. Instead of subsidizing lucrative industries, it can focus on domestic gaps ignored by commercial interests. The government should prioritize health needs over industry desires and ensure its biomanufacturing investments are utilized effectively. For instance, the idle Biologics Manufacturing Centre in Montreal could be a valuable asset for meeting domestic and global needs for critical treatments.
In conclusion, these parliamentary studies are a call to action. Canada must decide whether its pharmaceutical strategy will prioritize patients or profits. The implications are far-reaching, and the time to act is now. Will Canada choose to empower its citizens or continue down a path that may leave them vulnerable? The answer lies in the hands of these committees and the public's engagement in this critical discussion.
